Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2020.05.02.20088898: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementPotential participants then received a confirmation by email, which included a link to a questionnaire and a consent form to complete at home and bring on the day of the study visit.RandomizationMethods Study Design Each week, ~1300 randomly selected previous participants of the Bus Santé study with an email address on file (n~10’072, Figure S1) were invited to participate in the SEROCoV-POP study by email, which provided a link to an online appointment booking system for a visit at one of two sites within the proceeding seven days.Blindingnot detected.Power Analysisnot detected.Sex as a biological variableResults: In the first three weeks, we enrolled 1335 participants coming from 633 households, with 16% <20 years of age and 53.6% female, a distribution similar to that of Geneva.

    Table 2: Resources

    Antibodies
    SentencesResources
    We tested each participant for antiSARS-CoV-2-IgG antibodies using a commercially available enzyme-linked immunosorbent assay (Euroimmun AG, Lübeck, Germany).
    antiSARS-CoV-2-IgG
    suggested: None
    Laboratory Analyses We assessed anti-SARS-CoV-2-IgG antibodies using a commercially available enzyme-linked immunosorbent assay (Euroimmun AG, Lübeck, Germany # EI 2606-9601 G) targeting the S1-domain of the spike protein of SARS-CoV-2; sera diluted 1:101 were processed on a EuroLabWorkstation ELISA.
    anti-SARS-CoV-2-IgG
    suggested: None
    Further, we show that three weeks after the peak of confirmed cases, only 1 in 10 people has developed antibodies against SARS-CoV-2, even in one of the more heavily affected areas in Europe 13.
    SARS-CoV-2
    suggested: (Sino Biological Cat# 40143-R019, AB_2827973)
    To our knowledge, this is the first study to perform a large-scale seroprevalence survey of anti-SARSCoV-2 IgG antibodies where participants were selected from a representative sample of the general population.
    anti-SARSCoV-2 IgG
    suggested: None

    Results from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.